Renhuang to Launch New All-Natural Anti-depressant and Nerve Regulation Product - Compound Schisandra Tablets
HARBIN, China, June 22 /PRNewswire-Asia-FirstCall/ -- Renhuang Pharmaceuticals, Inc. (Pink Sheets: RHGP) ("Renhuang" or the "Company"), a developer, manufacturer and distributor of botanical products, bio-pharmaceuticals and traditional Chinese medicines ("TCM"), today announced that the Company plans to launch its new all-natural anti-depressant and nerve regulation product - Compound Schisandra Tablets ("Schisandra Tablets"), a single plant based medicine, in July 2010. Renhuang estimates that Schisandra Tablets will generate revenues of RMB 3.0 million (approximately $44,000) in fiscal year 2010.
Schisandra, also known as magnolia vine, has been clinically proven to have significant benefits to the functioning and regulation of the central nervous system and for upper body respiration. According to China Pharmacopoeia, Schisandra is used as a remedy for many ailments, such as: to generate body fluids and alleviate thirst, nourish the kidneys, cure insomnia and palpitations, and is also widely used as treatment for neurasthenia (a term most commonly used in Traditional Chinese medicine to denote a complex of symptoms characterized by chronic fatigue and weakness, loss of memory, and generalized aches and pains).
"Compound Schisandra Tablets are an exciting new plant-based anti-depressant and nerve regulation product, which complements our existing product portfolio, provides additional revenue generation opportunities and strengthens our leading market position in this important and rapidly growing market segment," commented Mr. Shaoming Li, Chairman and Chief Executive Officer of Renhuang. "We plan to extensively promote this new product to instill strong mark